UPDATE: Mizuho Securities Starts eFFECTOR Therapeutics, Inc. (EFTR) at

October 4, 2021 4:19 AM EDT
Get Alerts EFTR Hot Sheet
Price: $13.01 +2.44%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 13 | New: 72
Trade Now! 
Join SI Premium – FREE
(Updated - October 4, 2021 4:51 AM EDT)

Mizuho Securities analyst Mara Goldstein initiates coverage on eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) with a rating and a price target of $20.00.

The analyst comments "We initiate coverage on EFTR with a BUY rating and $20 price target. EFTR is developing drugs (tomivosertib, zotatifin) that are selective translational regulator inhibitors. They are able to simultaneously inhibit production of multiple proteins (that drive cancer) by targeting where those pathways converge. Central to our thesis is lead candidate's potential to show meaningful clinical and commercial viability over the next year (key top line data readouts to begin in 1H22). Given the company's emergence to the public market via SPAC this year, we see opportunity for the share price appreciation as data readouts approach."

For an analyst ratings summary and ratings history on eFFECTOR Therapeutics, Inc. click here. For more ratings news on eFFECTOR Therapeutics, Inc. click here.

Shares of eFFECTOR Therapeutics, Inc. closed at $13.15 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Mara Goldstein, SPAC